Biodexa Pharmaceuticals
BDRX
8 hedge funds and large institutions have $693K invested in Biodexa Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and closing their positions.
1,141% more capital invested
Capital invested by funds: $55.8K → $693K (+$637K)
100% more funds holding
Funds holding: 4 → 8 (+4)
35.04% more ownership
Funds ownership: 1.36% → 36.39% (+35%)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.09M |
| 2 |
AC
Armistice Capital
New York
|
+$569K |
| 3 |
HF
HRT Financial
New York
|
+$60.2K |
| 4 |
GI
GAMMA Investing
Foster City,
California
|
+$2.42K |
| 5 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$114 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$27.5K |
| 2 |
SS
SBI Securities
Tokyo,
Japan
|
-$85 |
BDRX Hedge Fund Activity: Q4 2025 in Review
8 of the 8,281 institutional investors tracked by Wall St. Rank reported a position in Biodexa Pharmaceuticals (BDRX) for Q4 2025, worth a combined $693K — up 1,141% from $55.8K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new BDRX positions and 0 closed out — a net gain of 4 holders — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $1.09M. The largest seller was UBS Group, cutting an estimated $27.5K.
- 8 institutional investors held Biodexa Pharmaceuticals (BDRX) as of Q4 2025, up from 4 in Q3 2025.
- Funds reported $693K of Biodexa Pharmaceuticals stock for Q4 2025, up 1,141% quarter-over-quarter.
- 4 funds opened new Biodexa Pharmaceuticals positions in Q4 2025 and 0 closed out, a net change of +4 holders.
- The largest Biodexa Pharmaceuticals buyer in Q4 2025 was Sabby Management, an estimated $1.09M added.
- The largest Biodexa Pharmaceuticals seller in Q4 2025 was UBS Group, an estimated $27.5K sold.
Based on aggregated 13F filings for Q4 2025.